Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 305-309

  Rossi, Alessandro ^a   Pacifico, Roberta ^a   Stratta, Paolo ^b  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b ASL 4   (Italy)

Author keywords

Attitude toward medication; Drug attitude inventory; Structural equation models

Indexed keywords

EID: 83655183356     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S5590     Document Type: Article

References (28)

1. Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia. Second edition. Am J Psychiatry. 2004;161(2 Suppl):1-56.
2. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19:609-618.
3. Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medications: what are they and are they being achieved? CNS Drugs. 1995;4:8-16.
4. Rosenstock IM. The health belief model and preventive health behaviour. Health Educ Monogr. 1974;2:354-383.
5. Bebbington PE. The content and context of compliance. Int Clin Psychopharmacol. 1995;9(Suppl 5):41-50.
6. Awad AG, Voruganti LNP, Heslegrave RJ, Hogan TP. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol. 1996;11(Suppl 2):55-60.
7. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
8. Weiden P, Rapkin B, Mott T, et al. Rating of medications influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297-310.
9. Naber DA. A self-rating scale to measure subjective effects of neuroleptic drugs, relationship to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(Suppl 3):133-138.
10. Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56:37-46.
11. Hofer A, Kemmler G, Eder U, Honeder M, Hummer M, Fleischhacker WW. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry. 2002;63(1):49-53.
12. Day J, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication. the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62:717-724.
13. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and Insight. Compr Psychiatry. 1998;39:215-219.
14. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry. 1996;169:444-450.
15. Sajatovic M, Rosch DS, Sivec HJ, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv. 2002;53:1319-1321.
16. Rossi A, Bagalà A, Del Curatolo V, et al. Remission in schizophrenia: one-year Italian study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder. Hum Psychopharmacol (submitted).
17. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004;65:1372-1376.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th. edition revised). American Psychiatric Association: Washington DC; 1994.
19. Kay SR. Positive and Negative Syndromes in Schizophrenia: Assessment and Research (Clinical and Experimental Psychiatry). New York, NY: Brunner-Mazel Inc; 1991.
20. Daneluzzo E, Arduini L, Rinaldi O, et al. PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component. Schizophr Res. 2002; 56:129-136.
21. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry. 1976;33:766-771.
22. Rossi A, Arduini L, De Cataldo S, Stratta P. Gli aspetti soggettivi del trattamento con farmaci antipsicotici: studio di validazione della versione italiana della Drug Attitude Inventory (DAI). Epidemiol Psichiatr Soc. 2001;10:107-113.
23. Kaplan, DW. Structural Equation Modeling: Foundations and Extensions. SAGE Publications: California; 2000.
24. Hofer A, Fleischhacker W. Attitudes towards medication in patients with schizophrenia. Acta Psychiatr Scand. 2006;113(3):161-162.
25. Awad G, Voruganti L. New antipsychotics, compliance, quality of life, and subjective tolerability. Are patients better off? Can J Psychiatry. 2004;49:297-302.
26. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry. 1992;149: 1148-1156.
27. Bebbington PE, Angenermyer M, Azorin JM, Marwaha S, Marteau F, Toumi M. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand. 2009; 119(Suppl 438):22-28.
28. Zygmunt A, Olfson M, Boyer CA, Mechanic D: Intervention to improve adherence in schizophrenia. Am J Psychiatry. 2002;159:1653-1664.